Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Ten years of hormone therapy reduces breast cancer recurrence without compromising quality of life

Share :

2016 ASCO Annual Meeting

3 - 7 Jun 2016
Published: 5 Jun 2016
Views: 1966
Rating:
Save
Dr Julie Lemieux - Hôpital du Saint-Sacrement, Québec, Canada

Dr Lemieux presents at ASCO 2016, a randomised phase III clinical trial, MA.17R found that postmenopausal women with early breast cancer benefit from extending aromatase inhibitor (AI) therapy with letrozole from 5 to 10 years.

Read the news story or watch the video interview for more.

Related Videos

Key insights on breast cancer in Cape Verde

Dr Pamela Borges - Agostinho Neto University Hospital, Praia, Cape Verde
Key insights on breast cancer in Cape Verde ( Dr Pamela Borges - Agostinho Neto University Hospital, Praia, Cape Verde )
12 Jan 2026

Transforming cancer care in India: The Access Cancer Care Initiative

Prof Richard Sullivan, Dr Ishu Kataria and Dr Arunah Chandran
Transforming cancer care in India: The Access Cancer Care Initiative ( Prof Richard Sullivan, Dr Ishu Kataria and Dr Arunah Chandran )
17 Jul 2025

Burden and trends of breast cancer worldwide: Opportunities for prevention?

Dr Eileen Morgan, Dr Isabelle Soerjomataram and Dr Shalaka Joshi
Burden and trends of breast cancer worldwide: Opportunities for prevention? ( Dr Eileen Morgan, Dr Isabelle Soerjomataram and Dr Shalaka Joshi )
10 Jul 2025

The added value of integrative medicine

Dr Marta Capelan, Dr Beth DuPree and Rosa Olmos
The added value of integrative medicine ( Dr Marta Capelan, Dr Beth DuPree and Rosa Olmos )
1 Apr 2025

Insights into germline genetic screening of breast cancer patients

Dr Teresa Ramón y Cajal, Dr Marjanka Schmidt and Dr Seigo Nakamura
Insights into germline genetic screening of breast cancer patients ( Dr Teresa Ramón y Cajal, Dr Marjanka Schmidt and Dr Seigo Nakamura )
10 Jan 2025

Post-diagnosis diet, nutrition and cancer prognosis

Dr Doris Chan - Imperial College London, London, UK
Post-diagnosis diet, nutrition and cancer prognosis ( Dr Doris Chan - Imperial College London, London, UK )
24 Oct 2024

ERBB2 amplifications across sex, race, and cancer types studied to guide HER2 therapies

Dr Marc Machaalani - Dana-Farber Cancer Institute, Boston, USA
ERBB2 amplifications across sex, race, and cancer types studied to guide HER2 therapies ( Dr Marc Machaalani - Dana-Farber Cancer Institute, Boston, USA )
14 Sep 2024

Trastuzumab deruxtecan effective against brain metastases in HER2-positive breast cancer

Dr Nancy Lin - Dana-Farber Cancer Institute, Boston, USA
Trastuzumab deruxtecan effective against brain metastases in HER2-positive breast cancer ( Dr Nancy Lin - Dana-Farber Cancer Institute, Boston, USA )
14 Sep 2024

Patient reported outcomes for telisotuzumab vedotin in c-Met protein overexpressing EGFR WT nonsquamous NSCLC

Prof Nicolas Girard - Institut Curie, Paris, France
Patient reported outcomes for telisotuzumab vedotin in c-Met protein overexpressing EGFR WT nonsquamous NSCLC ( Prof Nicolas Girard - Institut Curie, Paris, France )
14 Sep 2024

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation